Print

HVTN 097

This 1b randomized double blind placebo controlled clinical trial evaluates the safety and immunogenicity of the vaccine regimen ALVAC-HIV (vCP1521) followed by AIDSVAX? B/E in healthy, HIV-1 uninfected adult participants in South Africa. The study further attempts to elucidate immune responses to the HIV vaccine regimen, by comparing them to immune responses elicited by licensed tetanus or hepatitis B vaccines.

Trial Details:

I Completed
HIV Vaccine Trials Network (HVTN) April 15, 2013
ALVAC-HIV vCP1521,AIDSVAX B/E Canarypox Env B,E; Protein Env B,E
ALVAC-HIV vCP1521 Viral Vector - Pox
AIDSVAX B/E Protein
South Africa 100
NCT02109354
https://clinicaltrials.gov/ct2/show/NCT02109354?term=hvtn+097&rank=1